Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-453 in relapsed malignant mesothelioma
CTR20192180Phase 2Terminated
- Sponsor
- HUTCHMED
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in mesothelioma, sponsored by HUTCHMED. Started Nov 2019; status: terminated.
02
Drugs
fanregratinib
03
Conditions
mesothelioma
Beyond the preview
Go deeper on CTR20192180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192180.